Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer


Cite item

Full Text

Abstract

In a recent randomized, double-blind, phase III clinical trials among patients with metastatic castration-resistant prostate cancer (CRPC) progressing on androgen-deprivation therapy or after docetaxel chemotherapy, abiraterone acetate was shown to significantly prolong radiographic progression free survival and overall survival compared with prednisone alone, even in symptomatic patients and patients having visceral metastases and high level of prostate specific antigen at baseline. Here we present our own experience with abiraterone acetate in patients who represent negative prognostic factors of castration-resistant prostate cancer outside of clinical trials. 25 metastatic CRPC patients were treated with abiraterone acetate from 2012 to 2014.

About the authors

Ya V Gridneva

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

канд. мед. наук, врач отд-ния урологии

V B Matveev

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

д-р мед. наук, проф., зав. отд-нием урологии

D Z Kupchan

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

рук. отд-ния организации и проведения клинических исследований

S A Kalinin

ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва

ассистент каф. онкологии и лучевой терапии

M V Peters

ГБОУ ДПО РМАПО Минздрава России, Москва

ассистент каф. онкологии

References

  1. Hellerstedt B.A, Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154-79.
  2. Snoek R, Cheng H, Margiotti K et al. In vivo knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors. Clin Cancer Res 2009; 15: 39-47.
  3. Scher H.I, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59.
  4. Tannock I.F, De Wit R, Berry W.R et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
  5. Petrylak D.P, Tangen C.M, Hussain M.H et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
  6. Saad F, Gleason D.M, Murray R et al. A randomized, placebo - controlled trial of zoledronic acid in patients with hormone - refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68.
  7. Sternberg C.N, Petrylak D.P, Sartor O et al. Multinational, double - blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate - refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-8.
  8. Engel-Nitz N.M, Alemayehu B, Parry D, Nathan F. Differences in treatment patterns among patients with castration - resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Manag Res 2011; 3: 233-45.
  9. Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population - based study of prostate cancer chemotherapy. Clin Oncol (R Coll Radiol) 2011; 23: 706-8.
  10. Kantoff P.W, Higano C.S, Shore N.D et al. Sipuleucel-T immunotherapy for castration - resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
  11. Mottet N et al. Guidelines on prostate cancer. Eur Urol 2014; 65 (1): 124-37; Eur Urol 2014; 65 (2): 467-79.
  12. Berthold D.R et al. Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival Analysis in the TAX 327 study. J Clin Oncol 2008; 26: 242-5.
  13. Attard G, Reid A.H, A’Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration - resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8.
  14. Attard G, Reid A.H, De Bono J.S. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol 2010; 28 (29): e560-e561.
  15. Attard G, Reid A.H, Yap T.A et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration - resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-71.
  16. Danila D.C, Morris M.J, De Bono J.S et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel - treated castration - resistant prostate cancer. J Clin Oncol 2010; 28:1496-501.
  17. Reid A.H, Attard G, Danila D.C et al. Significant and sustained antitumor activity in post docetaxel, castration - resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489-95.
  18. Ryan C.J, Smith M.R, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration - resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28:1481-8.
  19. De Bono J.S, Logothetis C.J, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
  20. Fizazi K, Scher H.I, Molina A. Abiraterone acetate for treatment of metastatic castration - resistant prostate cancer: final overall survival analysis of the COU- AA-301 randomised, double - blind, placebo - controlled phase 3 study. Lancet Oncol 2012; 13 (Issue 10): 983-99.
  21. Ryan C.J, Smith M.R, De Bono J.S. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med 2013; 368 (2): 138-48.
  22. Jr Goodman O.B et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration - resistant cancer. Prostate Cаncer Prostatic Dis 2014; 17: 34-9.
  23. Rathkopf D.E. Genitourinary Cancers Symposium. J Clin Oncol 2013; 31 (Suppl. 6): 5.

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies